Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment

ClinicalTrials.gov ID: NCT01727440

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01727440. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this study is to enroll 250 participants that have joined the MURDOCK Study Horizon 1.5 (Duke IRB Pro00011196) with a current or prior diagnosis of severe acne AND current or prior treatment with oral isotretinoin. All 250 participants will answer a 5-page questionnaire designed to collect information on the diagnosis of severe acne and response to oral isotretinoin treatment. The aim is to identify genetic predictors of severe acne vulgaris and the outcome of oral isotretinoin treatment.

Study identification

NCT ID: NCT01727440
Recruitment status: Completed
Study type: Observational
Phase: Not listed
Lead sponsor: Duke University; Other
Enrollment: 123 participants

Conditions and interventions

Conditions

Interventions

Not listed

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2011 (Type not available)
Primary completion: Aug 2015 (Actual)
Completion: Aug 2015 (Actual)
Last update posted: Aug 24, 2017

2011 – 2015

United States locations

U.S. sites: 6
U.S. states: 1
U.S. cities: 5

Facility	City	State	ZIP	Site status
Carolinas Medical Center Northeast Medical Arts Building	Concord	North Carolina	28025	—
Dermatology Group of the Carolinas	Concord	North Carolina	28025	—
Ada Jenkins Center	Davidson	North Carolina	28036	—
Harrisburg Sleep Center	Harrisburg	North Carolina	28075	—
Lake Norman Community Health Clinic	Huntersville	North Carolina	28078	—
Kannapolis Internal Medicine	Kannapolis	North Carolina	28081	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01727440, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 24, 2017 · Synced Nov 15, 2026